BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6487460)

  • 1. Pinacidil monotherapy for hypertension.
    Ward JW
    Br J Clin Pharmacol; 1984 Aug; 18(2):223-5. PubMed ID: 6487460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary evaluation of pinacidil in hypertension.
    Ramsay LE; Freestone S
    Br J Clin Pharmacol; 1983 Sep; 16(3):336-8. PubMed ID: 6626426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension.
    Koliopoulos K; Papadoyannis DE; Karatzas NB
    Eur J Clin Pharmacol; 1984; 27(3):287-9. PubMed ID: 6510455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator.
    Breen EG; Mulhall D; Keogh JA
    Eur J Clin Pharmacol; 1985; 28(4):381-6. PubMed ID: 4029244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study.
    Goldberg MR; Offen WW
    Drugs; 1988; 36 Suppl 7():83-92. PubMed ID: 3076140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life on antihypertensive therapy: a double-blind trial comparing quality of life on pinacidil and nifedipine in combination with a thiazide diuretic. European Pinacidil Study Group.
    Fletcher AE; Battersby C; Adnitt P; Underwood N; Jurgensen HJ; Bulpitt CJ
    J Cardiovasc Pharmacol; 1992 Jul; 20(1):108-14. PubMed ID: 1383618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive efficacy of pinacidil--automatic ambulatory blood pressure monitoring.
    Zachariah PK; Sheps SG; Schirger A; Fisher LD; Shub C; Collins JB; Spiekerman RE
    Eur J Clin Pharmacol; 1986; 31(2):133-41. PubMed ID: 3803413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of pinacidil in hypertensive dialysis patients.
    Breen EG; Mulhall D; Keogh JA
    Eur J Clin Pharmacol; 1985; 28(4):375-80. PubMed ID: 4029243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension.
    D'Arcy V; Laher M; McCoy D; Sullivan P; Walsh CH; Hickey MP
    Eur J Clin Pharmacol; 1985; 28(3):347-9. PubMed ID: 4007040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension.
    Carlsen JE; Kardel T; Jensen HA; Tangø M; Trap-Jensen J
    Eur J Clin Pharmacol; 1983; 25(4):557-61. PubMed ID: 6653652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension.
    Izzo JL; Licht MR; Smith RJ; Larrabee PS; Radke KJ; Kallay MC
    Am J Cardiol; 1987 Aug; 60(4):303-8. PubMed ID: 2887102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative trial of pinacidil versus prazosin in mild to moderate arterial hypertension.
    Sterndorff B; Johansen P
    Drugs; 1988; 36 Suppl 7():64-6. PubMed ID: 3076137
    [No Abstract]   [Full Text] [Related]  

  • 13. Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension.
    Goldberg MR; Rockhold FW; Offen WW; Dornseif BE
    Clin Pharmacol Ther; 1989 Aug; 46(2):208-18. PubMed ID: 2758730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
    Friedel HA; Brogden RN
    Drugs; 1990 Jun; 39(6):929-67. PubMed ID: 2196168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous pinacidil in the acute treatment of hypertension.
    Rijk MC; Thien T
    J Clin Pharmacol; 1987 Jul; 27(7):468-74. PubMed ID: 3308975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term haemodynamic effects of pinacidil and hydralazine in arterial hypertension.
    Carlsen JE; Jensen HA; Rehling M; Lund JO; Trap-Jensen J
    Drugs; 1988; 36 Suppl 7():55-63. PubMed ID: 3076136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind comparator trials with pinacidil, a potassium channel opener.
    Callaghan JT; Goldberg MR; Brunelle R
    Drugs; 1988; 36 Suppl 7():77-82. PubMed ID: 3076139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin.
    Goldberg MR; Sushak CS; Rockhold FW; Thompson WL
    Clin Pharmacol Ther; 1988 Jul; 44(1):78-92. PubMed ID: 3292105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels.
    Goldberg MR
    J Cardiovasc Pharmacol; 1988; 12 Suppl 2():S41-7. PubMed ID: 2466178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pinacidil on blood pressure, plasma catecholamines and plasma renin activity in essential hypertension.
    Muiesan G; Fariello R; Muiesan ML; Christensen OE
    Eur J Clin Pharmacol; 1985; 28(5):495-9. PubMed ID: 3899669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.